• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

How Many Would Benefit From an Out-of-Pocket Cap on Insulin?

Article

Kaiser Family Foundation researcher found that 26% of those with an insulin prescription who have bought health insurance coverage in the individual market would benefit from a cap of $35 on monthly out-of-pocket costs for insulin.

Democrats and Republicans don’t agree on much. Caps on out-of-pocket costs for insulin might be an exception to the rule. Bipartisan talks are underway that would put a $35-per-month cap on out-of-pocket insulin costs. Some of the bills under consideration would also require insurers to cover at least one dosage form (pen, vial) of each type of insulin — rapid-acting, short-acting, intermediate-acting and so on.

Researchers at Kaiser Family Foundation set out to calculate how many people with private health insurance would benefit from such a cap. In other words, how many people pay more than $35 a month for insulin.

Using a 2018 claims database from private health plans, they identified roughly 1 million people who had a prescription for insulin filled. Of those, 184,000 were covered by plan sold in the individual market, 105,000 by a plan sold in the small employer market, and 802,000 by a plan in the large employer market.

They found that 26% of those with individual market coverage paid more than $35 per month on average for their insulin prescription. In the small employer market, the percentage was 31%, and in the large market it was 19%.

Of course, the savings would be greater for some than others depending on their plan’s coverage. The Kaiser Family Foundation researchers found that for more than 1 in 20 insulin users with private insurance pay more than $150 per month for their insulin, so for that group would save at least $115 a month if a $35 cap were imposed.

But, as the foundation researchers note, a ceiling on out-of-pocket costs does not deal directly with the prices that insulin makers are charging. If out-of-pocket costs are limited that may shift added cost to health plans, which, in turn, may put upward pressure on premiums.

There is a chance, though, that lower out-of-pocket costs will indirectly benefit payers if people are more adherent and need fewer medical services as a result.

Related Videos
Video 9 - "Denial of Coverage in Fertility Care"
Video 8 - "Risks of Miscarriage and Multiple Births Associated with Fertility Care"
Video 7 - "Fertility Preservation: Egg Freezing Versus Embryo Freezing"
Video 6 - "Family Building Costs, Barriers, and Dropout Rates Associated with Fertility Care"
Video 5 - "Closing Payer Gaps and Improving Fertility Care Access"
Video 4 - "Increasing Employer Coverage and Maximizing Fertility Benefits "
Video 5 - "Relevance of NUTURE Study Findings for Patients, Payers, Providers"
Video 3 - "Improving IVF Success Rates & Utilizing AI in Fertility Health Care"
Video 2 - "Holistic Fertility Management and Payer Collaboration"
Video 5 - "Relevance of NUTURE Study Findings for Patients, Payers, Providers"
Related Content
© 2024 MJH Life Sciences

All rights reserved.